Entest BioMedical, Inc. (OTC Pink: ENTB) is a biotechnology company that focuses on treatments for dogs and animals. Shares of the animal medical treatment company are rallying 13.85%, through early trading on Wednesday, April 26, 2017. Over the past month, Entest BioMedical, Inc. has seen average daily volume of 54,395 shares. However, volume of 1.56 million shares or dollar volume of $69,264, has already exchanged hands on Wednesday.

Shares of Entest BioMedical, Inc. are climbing today, after the company announced an update on its subsidiary, Zander Therapeutics, Inc.’s cancer treatments for dogs. The subsidiary has expanded its management team, hired scientific advisors, filed patents, cancer treatment compound expansion, and beginning of ex vivo studies on the compound. Here is the full press release detailing of the subsidiary updates:

Entest BioMedical, Inc. Press Release:

SAN DIEGO, April 26, 2017 /PRNewswire/ –Entest BioMedical Inc.’s (OTCPINK: ENTB) Chairman and CEO David Koos discussed current and anticipated developments for the company’s subsidiary, Zander Therapeutics Inc. Specifically, Zander Therapeutics is moving forward in the area of immunotherapy delivered through small molecule treatments. The company is the exclusive licensee for veterinary applications of Regen BioPharma’s intellectual property for modulating the checkpoint NR2F6 to treat cancer and arthritis.

“We believe that because dog DNA is very similar to human DNA, Zander Therapeutics will be able to piggy-back on advances made in medicinal chemistry by its licensor, Regen BioPharma. This greatly reduces our cost to enter this veterinary market space. Our goal is to take this licensed intellectual property, combine it with our own discoveries and produce small molecule therapies that treat cancer and arthritis in dogs,” stated Chairman David Koos. “The veterinary medicine market is believed to be $63 billion per year. With 50% of all dogs over the age of 10 contracting cancer in some form, not only is this an emotionally compelling story, it is an economically sound business model.”

Mr. Koos noted the following key milestones achieved by Zander Therapeutics:

  1.  Expansion of the management team.
  2.  Appointment of strong scientific advisors to help guide the company forward
  3.  Filing of patent applications for small molecule therapies in animals
  4.  Medicinal chemistry refinement and expansion of compounds modulating checkpoint NR2F6 (through licensor)
  5.  Initiation of ex vivo studies on modulating NR2F6 in canines through ChemDiv, Inc. (a well-respected contract research organization)

Harry Lander, PhD, Zander’s President and Chief Scientific Officer, noted, “The technology that Zander in-licensed gave the company a fast start in moving forward with small molecule therapies in the veterinary market. The company is very excited to be in a position to help animals with cancer and arthritis. As the ex vivo studies continue and the medicinal chemistry refines our compounds, I believe the company has a strong future.”

“The human side of immunological therapies for treating cancer are a hot bed of research. One striking example of this field moving forward is the recent announcement by Novartis of 80% remissions in its recent cancer cell therapy clinical trial http://www.thepharmaletter.com/article/more-than-80-complete-remission-rate-in-novartis-car-t-therapy-trial. Another is KITE Pharma announcing filing with the FDA for marketing approval of its cellular therapy http://www.thepharmaletter.com/article/first-car-t-therapy-bla-filing-initiated-with-us-fda. We at Zander Therapeutics intend to accelerate the rate of our veterinary immunology research progress, the objective being to make available to animals advances in therapies comparable to what is being developed in the field of human medicine,” added David Koos, Chairman and CEO of Zander Therapeutics Inc.

About Zander Therapeutics, Inc.:

Zander Therapeutics is a subsidiary of Entest BioMedical, Inc. (OTCPink: ENTB), a publicly-traded biotechnology company focused on veterinary medicine. The company seeks to develop small molecule and immune stimulating therapies for veterinary applications.

Currently, the company’s major interest is in developing small molecule therapies for treating cancer and autoimmune diseases in animals, which include arthritis.

Zander Therapeutics Inc. is the exclusive licensee for veterinary applications of Regen BioPharma Inc.’s (OTCQB: RGBP) (OTCQB: RGBPP) intellectual property and technology relating to NR2F6. NR2F6 is a molecular switch known as a ‘orphan nuclear receptor’, which controls genes associated with the immune response. Zander Therapeutics is solely focused on veterinary applications.

David Koos serves as Chairman and Chief Executive officer of Regen BioPharma, Inc. (OTCQB: RGBP), Entest BioMedical, Inc. (OTCPINK: ENTB) and Zander Therapeutics Inc. (wholly owned by Entest BioMedical, Inc.).

Disclaimer: This news announcement may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.

Add a Comment to this Post